Anthera Pharmaceuticals Inc Form 8-K August 09, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 9, 2016

ANTHERA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter)

Delaware	001-34637		20-1852016
(State or Other Jurisdiction of	(Commission Fi	la Numbar)	(I.R.S. Employer
Incorporation)	(Commission File Number)		(I.R.S. Employer Identification No.)
25801 Industrial Boulevard, Suite B, Hayward,		04545	
California		94545	
(Address of Principal Executive Offices)		(Zip Code)	

Registrant's telephone number, including area code: (510) 856-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On August 9, 2016 Anthera Pharmaceuticals, Inc. (the "Company") issued its second quarter 2016 press release. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

Exhibit No. Description 99.1 Press Release dated August 9, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 9, 2016 Anthera Pharmaceuticals, Inc.

By:/s/ May Liu May Liu Senior Vice President, Finance and Administration (Principal Accounting Officer)